Latest filings (excl ownership)
EFFECT
Notice of effectiveness
15 Mar 24
S-3
Shelf registration
1 Mar 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
29 Feb 24
8-K
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
3 Jan 24
S-8
Registration of securities for employees
13 Dec 23
8-K
Departure of Directors or Certain Officers
13 Dec 23
EFFECT
Notice of effectiveness
24 Nov 23
424B3
Prospectus supplement
22 Nov 23
CORRESP
Correspondence with SEC
20 Nov 23
UPLOAD
Letter from SEC
17 Nov 23
D
$88.15 mm in equity / options / securities to be acquired, sold $88.15 mm, 19 investors
16 Nov 23
S-3
Shelf registration
13 Nov 23
ARS
2022 FY
Annual report to shareholders
13 Nov 23
DEF 14A
Definitive proxy
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
13 Nov 23
8-K
VYNE Therapeutics Announces Private Placement of $88 Million
30 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
8-K
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development
1 May 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
9 Mar 23
8-K
Entry into a Material Definitive Agreement
28 Feb 23
8-K
Material Modifications to Rights of Security Holders
10 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
17 Jan 23
8-K
Results of Operations and Financial Condition
12 Jan 23
DEF 14A
Definitive proxy
25 Nov 22
D
$300.00 k in equity, sold $300.00 k, 1 investor
18 Nov 22
PRE 14A
Preliminary proxy
14 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Aug 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
12 Aug 22
8-K
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
10 Aug 22
DEFA14A
Additional proxy soliciting materials
28 Jul 22
Latest ownership filings
4
Tyler Zeronda
3 Apr 24
4
Iain Stuart
3 Apr 24
4
Mutya Harsch
3 Apr 24
4
David Domzalski
3 Apr 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
2 Feb 24
4
Tyler Zeronda
3 Jan 24
4
Iain Stuart
3 Jan 24
4
Mutya Harsch
3 Jan 24
4
David Domzalski
3 Jan 24
4
Elisabeth Sandoval
3 Jan 24
4
PATRICK G LEPORE
3 Jan 24
4
Anthony D Bruno
3 Jan 24
4
Steven L Basta
3 Jan 24
4
SHARON BARBARI
3 Jan 24
4
Christine Borowski
3 Jan 24
3
Christine Borowski
3 Jan 24
4
Tyler Zeronda
15 Dec 23
4
Iain Stuart
15 Dec 23
4
Mutya Harsch
15 Dec 23
4
David Domzalski
15 Dec 23
4
Elisabeth Sandoval
15 Dec 23
4
PATRICK G LEPORE
15 Dec 23
4
Anthony D Bruno
15 Dec 23
4
Steven L Basta
15 Dec 23
4
SHARON BARBARI
15 Dec 23
4
David Domzalski
4 Dec 23
4
PATRICK G LEPORE
17 Nov 23
SC 13G
CITADEL ADVISORS LLC
13 Nov 23
SC 13G
EVENTIDE ASSET MANAGEMENT, LLC
13 Nov 23
SC 13G
Cormorant Asset Management, LP
13 Nov 23
3
Len Blavatnik
13 Nov 23
SC 13D
AI Biotechnology LLC
13 Nov 23
SC 13G
Soleus Capital Master Fund, L.P.
2 Nov 23
4
Tyler Zeronda
4 Oct 23
4
Iain Stuart
4 Oct 23
4
Mutya Harsch
4 Oct 23
4
David Domzalski
4 Oct 23
4
Tyler Zeronda
5 Jul 23
4
Iain Stuart
5 Jul 23